These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22575318)

  • 1. Does slow and steady win the race?
    Howlett JG
    J Am Coll Cardiol; 2012 May; 59(20):1796-8. PubMed ID: 22575318
    [No Abstract]   [Full Text] [Related]  

  • 2. Heart rate in chronic heart failure: an overlooked risk factor.
    Komajda M
    Eur Heart J; 2015 Mar; 36(11):648-9. PubMed ID: 25416328
    [No Abstract]   [Full Text] [Related]  

  • 3. [Candesartan in heart failure: assessment of reduction in mortality and morbidity].
    Tsutsui H
    Nihon Rinsho; 2007 Apr; 65 Suppl 4():507-12. PubMed ID: 17508585
    [No Abstract]   [Full Text] [Related]  

  • 4. CHARMed - the effects of candesartan in heart failure.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Mar; 6(3):513-6. PubMed ID: 15794741
    [No Abstract]   [Full Text] [Related]  

  • 5. Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?
    Pitt B
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):70-1. PubMed ID: 16265371
    [No Abstract]   [Full Text] [Related]  

  • 6. [Angiotensin receptor blockers in heart failure. CHARM Study].
    Kochsiek K
    Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
    [No Abstract]   [Full Text] [Related]  

  • 7. HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
    McMurray JJ; Swedberg K
    Eur J Heart Fail; 2010 Feb; 12(2):99-103. PubMed ID: 20083618
    [No Abstract]   [Full Text] [Related]  

  • 8. [Conclusions from CHARM interview with Prof. Veselin Mitrovich, Bad Nauheim. Strong evidence: more help for weak hearts].
    Mitrovic V
    MMW Fortschr Med; 2005 Mar; 147(13):48-9. PubMed ID: 15832762
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardioprotection by means of Candesartan in cardiac insufficiency. CHARM overall partial evaluation (Candesartan in heart failure assessment of reduction in mortality and morbidity)].
    Tschöpe C; Schultheiss HP
    Internist (Berl); 2006 Oct; 47(10):1084-6. PubMed ID: 16988804
    [No Abstract]   [Full Text] [Related]  

  • 10. Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure.
    Meredith PA; Jarvis SC
    Int J Clin Pract; 2011 Aug; 65(8):911; author reply 912. PubMed ID: 21762314
    [No Abstract]   [Full Text] [Related]  

  • 11. Waste not, want not: free money, moral hazard and value-based prescribing.
    Minhas R
    Int J Clin Pract; 2011 Mar; 65(3):240-2. PubMed ID: 21284792
    [No Abstract]   [Full Text] [Related]  

  • 12. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 13. Easy money? Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class.
    Pitt B; Julius S
    Int J Clin Pract; 2011 Mar; 65(3):242-4. PubMed ID: 21284791
    [No Abstract]   [Full Text] [Related]  

  • 14. The CHARM programme.
    Pechlaner C
    Lancet; 2003 Nov; 362(9396):1675-6; author reply 1678-9. PubMed ID: 14630453
    [No Abstract]   [Full Text] [Related]  

  • 15. CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand).
    Cardiovasc J S Afr; 2004; 15(5):252. PubMed ID: 15483738
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
    Castagno D; Skali H; Takeuchi M; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pfeffer MA; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2012 May; 59(20):1785-95. PubMed ID: 22575317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.
    Vazir A; Claggett B; Jhund P; Castagno D; Skali H; Yusuf S; Swedberg K; Granger CB; McMurray JJ; Pfeffer MA; Solomon SD
    Eur Heart J; 2015 Mar; 36(11):669-75. PubMed ID: 25368202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candesartan for the management of heart failure: more than an alternative.
    McKelvie RS
    Expert Opin Pharmacother; 2006 Oct; 7(14):1945-56. PubMed ID: 17020420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CHARM programme.
    Penston J
    Lancet; 2003 Nov; 362(9396):1678; author reply 1678-9. PubMed ID: 14630459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.